Codiak BioSciences Inc is a biotechnology business based in the US. Codiak BioSciences shares (CDAK) are listed on the NASDAQ and all prices are listed in US Dollars. Codiak BioSciences employs 105 staff and has a trailing 12-month revenue of around USD$16.7 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$14.82|
|52-week range||$7.90 - $37.85|
|50-day moving average||$16.79|
|200-day moving average||$18.26|
|Wall St. target price||$36.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.79|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-10-08)||4.00%|
|1 month (2021-09-17)||-22.45%|
|3 months (2021-07-16)||-7.26%|
|6 months (2021-04-16)||15.06%|
|1 year (2020-10-16)||22.48%|
|2 years (2019-10-13)||N/A|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
|Revenue TTM||$16.7 million|
|Gross profit TTM||$-71,066,000|
|Return on assets TTM||-36.79%|
|Return on equity TTM||-442.29%|
|Market capitalisation||$330.9 million|
TTM: trailing 12 months
There are currently 515,832 Codiak BioSciences shares held short by investors – that's known as Codiak BioSciences's "short interest". This figure is 7.2% up from 481,053 last month.
There are a few different ways that this level of interest in shorting Codiak BioSciences shares can be evaluated.
Codiak BioSciences's "short interest ratio" (SIR) is the quantity of Codiak BioSciences shares currently shorted divided by the average quantity of Codiak BioSciences shares traded daily (recently around 69801.353179973). Codiak BioSciences's SIR currently stands at 7.39. In other words for every 100,000 Codiak BioSciences shares traded daily on the market, roughly 7390 shares are currently held short.
However Codiak BioSciences's short interest can also be evaluated against the total number of Codiak BioSciences shares, or, against the total number of tradable Codiak BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codiak BioSciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Codiak BioSciences shares in existence, roughly 20 shares are currently held short) or 0.0359% of the tradable shares (for every 100,000 tradable Codiak BioSciences shares, roughly 36 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Codiak BioSciences.
We're not expecting Codiak BioSciences to pay a dividend over the next 12 months.
Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc. , Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Cue Health—developer of a COVID-19 self-testing kit with conditional approval in the US, Canada, European Union and India—has gone public. Here’s how to buy in.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ITUB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing BSX stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing WM stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing MIN stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing LUC stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing GSV stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing FCU stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing AII stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing USA stock, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.